Loading...
•
Jun 30, 2022
Aytu BioScience Q4 2022 Earnings Report
Aytu BioPharma achieved record revenue in the fourth quarter and fiscal year 2022, driven by substantial growth in the Prescription segment and positive adjusted EBITDA within the same segment.
Key Takeaways
Aytu BioPharma reported record fourth quarter revenue of $27.4 million, a 17% increase year-over-year, driven by a 28% increase in prescription product revenue. The company's Prescription segment achieved positive adjusted EBITDA, while the Consumer Health segment experienced a slight revenue decrease due to supply chain disruptions.
Total net revenue reached a record $27.4 million, up 17% year-over-year.
Prescription product revenue hit a record $18.7 million, a 28% increase year-over-year.
ADHD product revenue increased by 21% to $12.2 million.
Prescription segment achieved positive Adjusted EBITDA of $1.1 million.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
Aytu BioPharma anticipates continued growth in its portfolio of prescription and consumer health products, expecting organic growth, operational efficiencies, and portfolio prioritization to drive positive adjusted EBITDA. The company is on track to remove approximately $15 million from its cost structure during fiscal years 2022 and 2023.
Positive Outlook
- Continued growth in prescription and consumer health products portfolio.
- Organic growth coupled with operational and manufacturing efficiencies.
- Portfolio prioritization driving towards positive adjusted EBITDA.
- On track to remove approximately $15 million from cost structure during fiscal 2022 and 2023.
- Advancement of AR101 in Phase 3 PREVEnt clinical trial.